In:
Angewandte Chemie, Wiley, Vol. 133, No. 19 ( 2021-05-03), p. 10831-10839
Abstract:
Manganese‐based contrast agents (MnCAs) have emerged as suitable alternatives to gadolinium‐based contrast agents (GdCAs). However, due to their kinetic lability and laborious synthetic procedures, only a few MnCAs have found clinical MRI application. In this work, we have employed a highly innovative single‐pot template synthetic strategy to develop a MnCA, MnL Me , and studied the most important physicochemical properties in vitro. MnL Me displays optimized r 1 relaxivities at both medium (20 and 64 MHz) and high magnetic fields (300 and 400 MHz) and an enhanced r 1 b =21.1 mM −1 s −1 (20 MHz, 298 K, pH 7.4) upon binding to BSA ( K a =4.2×10 3 M −1 ). In vivo studies show that MnL Me is cleared intact into the bladder through renal excretion and has a prolonged blood half‐life compared to the commercial GdCA Magnevist. MnL Me shows great promise as a novel MRI contrast agent.
Type of Medium:
Online Resource
ISSN:
0044-8249
,
1521-3757
DOI:
10.1002/ange.v133.19
DOI:
10.1002/ange.202100885
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
505868-5
detail.hit.zdb_id:
506609-8
detail.hit.zdb_id:
514305-6
detail.hit.zdb_id:
505872-7
detail.hit.zdb_id:
1479266-7
detail.hit.zdb_id:
505867-3
detail.hit.zdb_id:
506259-7
Bookmarklink